

## Special Issue

# Personalized Medicine in Lung Cancer: Diagnosis, Treatment and Prognosis

### Message from the Guest Editor

Lung cancer is the most common cause of cancer-related mortality worldwide. Although new therapeutic strategies are defined according to the molecular profile of the tissue, a high rate of these targeted therapies fail to cure the disease because of several biological and technological challenges, mainly the heterogeneity of the tumor. The purpose of this Special Issue, *Personalized Medicine in Lung Cancer: Diagnosis, Treatment and Prognosis*, is to highlight: 1) the benefit of personalized medicine in the diagnosis, treatment, and prognosis of lung cancer patients; 2) the new assays that could achieve high sensitivity for early detection of minimal residual disease (MRD) in lung cancer patients; 3) the crucial role of liquid biopsies in personalized medicine in lung cancer; and 4) the spatial heterogeneity as well as temporal heterogeneity between the primary tumor and local or distant recurrences in the same patient. Finally, we also wish to present the rapid development of technology and drugs in this area of research.

---

### Guest Editor

Dr. Athina N. Markou

Department of Chemistry, National and Kapodistrian University of Athens, 15771 Athens, Greece

---

### Deadline for manuscript submissions

closed (31 March 2022)



## Journal of Personalized Medicine

---

an Open Access Journal  
by MDPI

---

CiteScore 6.0  
Indexed in PubMed



[mdpi.com/si/95252](https://mdpi.com/si/95252)

*Journal of Personalized  
Medicine*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
jpm@mdpi.com

[mdpi.com/journal/](https://mdpi.com/journal/)

[jpm](https://jpm)





# Journal of Personalized Medicine

---

an Open Access Journal  
by MDPI

---

CiteScore 6.0  
Indexed in PubMed



[mdpi.com/journal/](https://mdpi.com/journal/)

[jpm](https://jpm)



## About the Journal

### Message from the Editor-in-Chief

*Journal of Personalized Medicine* is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on “omics”-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

---

### Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2, Canada

---

### Author Benefits

#### High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

#### Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 25 days after submission; acceptance to publication is undertaken in 5.8 days (median values for papers published in this journal in the second half of 2025).